TB-500 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-07-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
=== Neovascular glaucoma === Anti-VEGF agents as injectable medications, along with other standard of care treatment for decreasing intraocular pressure, may improve pressure in people with neovascular glaucoma for short periods. Evidence suggests that this improvement may last 4–6 weeks. There is no sufficient evidence to suggest that anti-VEGF medications are effective either for short-term or for longer-term treatment. The short, medium, and long-term safety of anti-VEGF treatment has not been well investigated.
== Model systems == Human models for cystinosin are typically derived from cystinotic renal tubular cell lines. Non-human protein homologs for cystinosin include ERS1 in Saccharomyces cerevisiae (yeast cells) and the Caenorhabditis elegans protein, C41C4.7. Murine ctns has also been used.
== French interlude and the Bourbon restoration == King Ferdinand was unable to consolidate his power. In 1806, faced with a French invasion by Napoleon Bonaparte's troops, he again had to take refuge in Palermo under the protection of the British navy. The Kingdom of Naples was entrusted by Napoleon to older brother Joseph Bonaparte. Numerous revolts did not mar in the continental Mezzogiorno, such as in Calabria, where the Calabrian Insurrection broke out, carried out by brigands, peasants and army stragglers, supported by British military units. To tame the three year long revolt, Napoleon committed two of the best French generals, André Masséna and Jean Maximilien Lamarque, who employed ruthless means, such as reprisal against entire villages that supported the brigands, as in the massacre of Lauria, perpetrated by Massena's soldiers. In spite of this, Napoleonic rule drove social and economic innovations and upheavals: on 2 August 1806, Joseph Bonaparte decreed the end of feudalism. He abolished baronial jurisdictions, feudal-like personal benefits, and prohibitory rights, i.e., monopolies on specific productive activities. Lands and property were put into liquidation and opened for commercial exploitation by the French government. These were purchased by members of the agrarian bourgeoisie, which was gaining political clout.
Sources: en.wikipedia.org
=== Toughness and hysteresis === The toughness of a hydrogel refers to the ability of the hydrogel to withstand deformation or mechanical stress without fracturing or breaking apart. A hydrogel with high toughness can maintain its structural integrity and functionality under higher stress. Several factors contribute to the toughness of a hydrogel including composition, crosslink density, polymer chain structure, and hydration level. The toughness of a hydrogel is highly dependent on what polymer(s) and crosslinker(s) make up its matrix as certain polymers possess higher toughness and certain crosslinking covalent bonds are inherently stronger. Additionally, higher crosslinking density generally leads to increased toughness by restricting polymer chain mobility and enhancing resistance to deformation. The structure of the polymer chains is also a factor in that, longer chain lengths and higher molecular weight leads to a greater number of entanglements and higher toughness. A good balance (equilibrium) in the hydration of a hydrogel leads is important because too low hydration causes poor flexibility and toughness within the hydrogel, but too high of water content can cause excessive swelling, weakening the mechanical properties of the hydrogel.
The dermis is the underlying connective tissue layer that supports the epidermis. It is composed of dense irregular connective tissue and areolar connective tissue such as a collagen with elastin arranged in a diffusely bundled and woven pattern. The dermis has two layers: the papillary dermis and the reticular layer. The papillary layer is the superficial layer that forms finger-like projections into the epidermis (dermal papillae), and consists of highly vascularized, loose connective tissue. The reticular layer is the deep layer of the dermis and consists of the dense irregular connective tissue. These layers serve to give elasticity to the integument, allowing stretching and conferring flexibility, while also resisting distortions, wrinkling, and sagging. The dermal layer provides a site for the endings of blood vessels and nerves. Many chromatophores are also stored in this layer, as are the bases of integumental structures such as hair, feathers, and glands.
No data are available concerning the possible reproductive, developmental, or carcinogenic effects of HMX. HMX is considered less toxic than TNT or RDX. Remediating HMX-contaminated water supplies has proven to be successful.
==== Breast cancer ==== In combination with low doses of herceptin, selective ADAM10 inhibitors decrease proliferation in HER2 over-expressing cell lines while inhibitors, that do not inhibit ADAM10, have no impact. These results are consistent with ADAM10 being a major determinant of HER2 shedding, the inhibition of which, may provide a novel therapeutic approach for treating breast cancer and a variety of other cancers with active HER2 signaling. The presence of the product of this gene in neuronal synapses in conjunction with protein AP2 has been seen in increased amounts in the hippocampal neurons of Alzheimer's disease patients.
Sources: en.wikipedia.org
Though it became a "forgotten drug" following the discovery of antibiotics in 1928, there has been a resurgence in interest in methenamine since 2010 owing to increasing rates of bacterial resistance with antibiotics. Larger and higher-quality clinical trials of methenamine for UTI prevention have started to be published in the 2020s and it may soon be recommended by more medical guidelines. Methenamine has been found to be more cost-effective than low-dose prophylactic antibiotics for preventing UTIs.
==== Chronic conditions ==== Breastfeeding is also associated with a lower risk of type 2 diabetes among mothers who practice it. Longer duration of breastfeeding is associated with reduced risk of hypertension. For breastfeeding women, long-term health benefits include reduced risk of breast cancer, ovarian cancer, and endometrial cancer. According to the American Heart Association, breastfeeding also reduces the risk of maternal heart disease and stroke. A 2011 review found it unclear whether breastfeeding affects the risk of postpartum depression. Later reviews have found tentative evidence of a lower risk among mothers who successfully breastfeed, though it is unknown whether breastfeeding decreases depression, or whether depression decreases breastfeeding.
It is also formed by the degradation of precursors such as some fluorotelomers. PFOA is used as a surfactant because it can lower the surface tension of water more than hydrocarbon surfactants while having exceptional stability due to having perfluoroalkyl tail group. The stability of PFOA is desired industrially but is a cause of concern environmentally. The primary manufacturer of perfluorooctanesulfonic acid (PFOS), 3M, began a production phase-out in 2002 in response to concerns expressed by the U.S. Environmental Protection Agency (EPA). Eight other companies agreed to gradually phase out the manufacturing of the chemical by 2015. By 2014, EPA had listed PFOA and perfluorooctanesulfonates (salts of perfluorooctanesulfonic acid, PFOS) as emergent contaminants:
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.